ABSTRACT-Risperidone was compared with antipsychotics hitherto used for in vitro receptor binding using animal brain or cloned (human) receptors and in vivo receptor occupancy in rat and guinea pig brain following acute treatment. Both in vitro and in vivo, risperidone, 9-OH-risperidone, SM-9018, clozapine and clocapramine showed higher affinity for 5-HT2A-than for D2-receptors, whereas mosapramine, haloperidol, bromperidol and nemonapride had a slight to strong preference for D2-compared to 5-HT2A-receptors. In vivo, risperidone showed the highest potency for 5-HT2A-receptor occupancy; To obtain the same extent of D2-receptor occupancy, a 19-times higher dosage was required. 9-OH-Risperidone, the principal active metabolite of risperidone, showed a receptor occupancy profile comparable to that of risperidone. No regional selectivity for D2-receptor occupancy in mesolimbic vs nigrostriatal areas was detected for any of the compounds. Risperidone differed from the other compounds by the remarkably shallow slope of its D2-receptor dose-occupancy curve. A greater predominance of 5-HT2A-receptor vs D2-receptor occupancy and a more gradual occupancy of D2-receptors differentiate risperidone from the other compounds. Both properties probably assist in preventing an extensive blockade of D2-receptors, the cause for extrapyramidal symptoms (EPS). The predominant 5-HT2A-receptor occupancy most likely underlies risperidone's beneficial effects on the negative symptoms of schizophrenia and an adequately low D2-receptor occupancy adds to the treatment of positive symptoms with a low liability of EPS.
Schizophrenia
is a devastating psychiatric disorder often with onset in puberty and lasting throughout life. It means a dramatic burden for the patient and others in his close environment. In addition to the mental suffering, the significant cost of the disease to society is to be considered (1, 2) . Although the disease can be manifested in several ways, schizophrenia is often characterized by the appearance of positive (hallucinations, delusions, disorganized speech, disorganized behavior) and negative symptoms (alogia, affective blunting, avolition, anhedonia/asociality, attention impairment); both symptoms, although independent, may coexist in the same patient (3 -5) . The etiology of schizophrenia is still not understood. Conventional neuroleptics have been widely used since the early 1960s for treatment of the positive symptoms of schizophrenia, and a correlation was established between the average daily therapeutic dose and their binding affinities to dopamine D2-receptors (6) . Although representing a breakthrough in the treatment of schizophrenic disorders, conventional neuroleptics displayed major shortcomings: the induction of neurological side-effects (dystonia, parkinsonism, akathisia, tardive dyskinesia) and a lack of efficacy for the treatment of the negative symptoms of schizophrenia (6, 7) . With the recent discovery of D3-and D4-receptors, the new subtypes of dopamine receptors (8, 9 ), hypotheses were raised about possible involvement of these receptors in the pathophysiology of schizophrenia (10); they have been proposed as potential targets for antipsychotic drugs.
Recently, renewed attention was paid to the role of serotonin in schizophrenia. Upon the discovery of 5-HT2
(now termed 5-HT2A)-receptors in 1978 (11), we noted that several neuroleptics bound to both 5-HT2A-and D2-receptors. Pipamperone (a butyrophenone derivative) stood out because of its predominant 5-HT2A-receptor interaction. This compound was noted in the clinic for its beneficial effect in socially withdrawn and agitated psychiatric patients and for normalizing disturbed sleep rhythms (12) . It suggested a beneficial role of 5-HT2A-receptor blockade for the treatment of schizophrenia. In subsequent studies, the potent and long acting 5-HT2A/2c-receptor antagonist ritanserin was found to alleviate negative symptoms in schizophrenics (13) and to reduce extrapyramidal symptoms (EPS) induced by neuroleptic treatment (14) . In animal studies it was shown that 5-HT2A antagonists reduced neuroleptic-induced catalepsy (15 -17) , that they were involved in the restoration of burst firing of dopaminergic neurons (18, 19) and that they would attenuate the effects of D2-receptor blockade in the striatum (20) . 5-HT2A antagonism was suggested to play a major role in the distinction between "atypical" and conventional neuroleptics (21) . With the introduction of risperidone (Risperdal®), it appeared that potent 5-HT2A antagonism combined with a milder D2 antagonism (22, 23) resulted in remarkably improved clinical properties. In addition to the treatment of the positive symptoms, risperidone was also capable of treating the negative symptoms of schizophrenia with a very low liability of extrapyramidal symptoms (24) (25) (26) .
In the present study, risperidone was compared to antipsychotics hitherto used to estimate the benefits of this new compound versus the available medication for the treatment of schizophrenia. For this purpose, in vitro receptor binding assays using tissue or cell membrane preparations were performed to detect the target neurotransmitter receptors of selected antipsychotic drugs. Secondly, the occupancy of these target receptors by the test-compounds was investigated in rat brain, 2 hr after s.c. administration. In vivo occupancy of the receptors was revealed by subsequent ex vivo radioligand binding in brain sections and quantified by autoradiography, according to a technique developed in this laboratory (27) . Fig. 1 .
Chemical structures of the test compounds.
MATERIALS AND METHODS
In vitro receptor binding Risperidone, 9-OH-risperidone, haloperidol, bromperidol, nemonapride, SM-9018, clozapine, clocapramine and mosapramine (chemical structures are shown in Fig.  1 ) were screened for inhibition of radioligand binding in vitro to neurotransmitter-, peptide-and lipid-derived factor receptors, ion channels and neurotransmitter transporters. Systems, radioligands and assay conditions are summarized in Table 1 . Neurotransmitter receptors that are targets for the compounds were further assayed in vitro using homogenates from animal brain or cloned (human) receptors stably expressed in mammalian cell lines. Compounds were incubated under the assay conditions described in Table 1 , at 10 to 12 concentrations between 10-11 to 10-5 M. Incubations were stopped by rapid filtration of the binding mixture over glass fiber filters (manual filtration manifold or Tomtec semi-automatic filtration); The filters were then rapidly rinsed, and membranebound radioactivity collected on the filters was determined by scintillation counting for tritiated ligands (Packard Tricarb or Wallac scintillation counter) or by using a gamma counter for iodinated ligands (Packard Cobra). Counts were directly captured in a computer. Data were further calculated and analyzed using automated procedures. Radioligand binding in the presence of non-labelled compound was expressed as a percent of the total binding and plotted against the log of the concentration of the compound. Hence, sigmoidal curves were generated. The curve of best fit was calculated by computerized curve fitting using equations as described by Oestreicher and Pinto (56) . pIC50-values (-log of the concentration producing 50% inhibition of specific radioligand binding) were derived from the curves. K;-values were calculated according to Cheng and Prusoff (57) . Experiments were repeated 2-5 times independently.
Drug treatment
Male Wistar rats (200 g) and male Dunkin-Hartley guinea pigs (300 g), both bred in own facilities, were treated with subcutaneous injections of saline or test compounds at 6 or 7 dose levels ranging from 0.0025 to 40 mg/kg body weight. Six to twelve animals were used per dose. The animals were sacrificed by decapitation 2 hr after drug administration. Brains were immediately removed from the skull and rapidly frozen in dry-ice cooled 2-methylbutane (-40°C). Twenty-micron-thick frontal sections were cut out of these brains using a ReichertJung 2800E cryostat-microtome (Cambridge Instruments, Cambridge, UK) and thaw-mounted on adhesive microscope slides (Star Frost, Knittel Glaser, Germany). The sections were then kept at -20 C until use.
Ex vivo radioligand binding in brain sections and quantitative autoradiography
The receptors for which the compounds revealed K;-values below 100 nM were studied for in vivo occupancy after acute treatment: where appropriate, occupancy of 5-HT1A-, 5-HT2A-, 5-HT2C-, D1-, D2-, D3-, a1-, a2-, cholinergic muscarinic-or H1-receptors was measured. The in vivo occupancy of D4-receptors could not be investigated since no reliable model was available for D4-binding in brain sections. Receptor occupancies were quantified in brain areas showing high receptor density, which were selected after regional distribution studies performed by ourselves and by others (58) (59) (60) (61) (62) . The selected brain regions and their precise localization are listed in Table 2 . Occupancy of all selected receptors was quantified in each individual brain (6 -12 animals per dose, 6-8 dosages).
Neurotransmitter receptors were labelled in brain sections, and autoradiograms were generated according to the protocols summarized in Table 2 . The following general procedure was applied: after thawing, sections were dried under a cold air stream. The sections were not washed prior to incubations in order to avoid dissociation of the drug-receptor complex. D3-receptors, however, can not be labelled in unwashed brain sections, due to occlusion by an endogenous substance likely to be dopamine (69) . A minimal preincubation (30 sec) was therefore applied to render D3-receptors partially accessible for [3H]7-OH-DPAT. Radioligand solution (200 pl) was applied on each section; incubation was restricted to 10 min at room temperature in order to minimize dissociation of the drug from the receptor. Brain sections of drug-treated and saline-treated animals were incubated in parallel, and the incubation time was rigorously controlled. Full association of the radioligand to the receptor was, in general, not achieved after 10 min of incubation. As a consequence, radioactive labelling of the receptors remained below its maximal level. This loss in radioactive signal was compensated for by using longer exposure times to generate the autoradiograms.
Non-specific binding was measured in adjacent sections, in the presence of an excess of an unlabelled competitor with chemical structure different from the radioligand (Table 3) . After the incubation, the excess of radioactivity was washed-off in consecutive baths of ice-cold buffer, followed by a quick rinse in icecold water. The sections were then dried under a cold-air stream, placed in a light-tight cassette and covered with a light-sensitive film. Ektascan GRL films (Kodak) were used for the generation of autoradiograms by iodinated ligands. After the exposure time, these films were deve- Ex vivo receptor labelling by the radioligand in brain sections of drug-treated animals was expressed as the percentage of receptor labelling in corresponding brain sections of saline-treated animals. Percent receptor occupancy by the drug administered to the animal was given by 100% minus the percent receptor labelling in the treated animal. Percent receptor occupancies were plotted vs dose. For each of the 6-8 doses per compound, individual values from 6-12 animals (mostly 6) were used. Each individual value was the mean of measurements performed in 3 consecutive sections. The sigmoid log dose-effect curve of best fit was calculated by non-linear regression analysis by a computer program using equations as described by Oestreicher and Pinto (56) . From these dose-response curves, the ED25-, ED50-and ED75-values (the drug dose producing 25010, 50% and 75% receptor occupancy, respectively) and the slopes of the curves for receptor occupancy were calculated. A nonoverlap of the 95010 confidence limits was considered to reflect biologically relevant differences. The drugs were obtained from the companies of origin. Risperidone, 9-OH-risperidone, haloperidol, bromperidol were from Janssen Pharmaceutica (Beerse, Belgium). Nemonapride was from Yamanouchi (Tokyo), SM-9018 was from Sumitomo (Osaka), clozapine was from Sandoz (Basel, Switzerland), clocapramine and mosapramine were from Yoshitomi (Osaka). 
RESULTS
In vitro competition binding of risperidone, 9-OHrisperidone, haloperidol, bromperidol, clozapine, nemonapride, SM-9018, clocapramine and mosapramine to neurotransmitter receptors or neurotransmitter transporters, as listed in Table 1 , was investigated using animal brain or cloned (human) receptors stably expressed in mammalian cell lines. Table 4 contains the in vitro receptor binding profiles (Ki-values) of the compounds tested in this study. Receptors for which a compound displayed a Ki-value below 100 nM were considered as potential targets for the compound and were selected for the investigation of in vivo receptor occupancy.
Autoradiograms representing the various binding models used, obtained after labelling of brain sections of saline-treated animals (maximal amount of available binding sites), were similar to those published previously (27) . (n=6-12) . The ED50-values (derived from the dose-occupancy curves) for the occupancy of the various target receptors by the testcompounds are listed in Table 5 . The slopes of the D2-, 5-HT2A-and adrenergic al-receptor occupancy curves are listed in Table 6 ; also included are the ED25-and ED75-values for the occupancy of D2-receptors in the caudateputamen (striatum). Data on D2-receptor occupancy in the caudate-putamen (striatum), substantia nigra and in the mesolimbic areas (nucleus accumbens and olfactory tubercle) are listed in Table 7 . 
DISCUSSION

Potency of interactions with dopamine receptors
In accordance with their antipsychotic properties, all compounds displayed affinity in vitro D2-receptors, but with a wide range of potency (Table 4) : nemonapride showed the highest affinity (subnanomolar, 5 times higher than haloperidol) and clozapine showed the lowest affinity for D2-receptors (100 times lower than haloperidol). The affinities of risperidone and 9-OH-risperidone for D2-receptors were two to three times lower than that of haloperidol. Clozapine was the only drug to show higher affinity in vitro for D4-receptors than D2-receptors. Its D4 affinity, however, was not very high. Nemonapride and SM-9018 had almost equivalent affinity for D4-and D2-receptors. Mosapramine had the lowest ratio, showing a 25-times lower affinity for D4-receptors than D2-receptors. D1 affinities were at least 100 times lower than the drug's D2 affinities, except for clocapramine (20 times lower) and clozapine (4 times lower). In vivo, mosapramine, haloperidol, bromperidol and nemonapride were confirmed to predominantly occupy D2-receptors, nemonapride being extremely potent, i.e., 27 times more potent than haloperidol ( Table 5 ). The rank order of potencies for D2-receptor occupancy was in good agreement with the in vitro binding affinities. Clocapramine, however, which had still a moderate affinity for D2-receptors in vitro, showed the lowest potency for D2-occupancy in vivo. Fifty percent occupancy of D2-receptors was not entirely reached by clocapramine at its highest dosage (40 mg/kg, s.c., 2 hr), indicating probably a more rapid clearance/metabolization of the compound. Its ED50 dose was estimated, under the present conditions, to be around 65 mg/kg in the rat caudate-putamen.
For most compounds, the ratio of D2-vs D3-occupancy potency in vivo was reduced as compared to the in vitro affinity ratio. This may be due to a competition with endogenous dopamine (35) , which shows nanomolar affinity for the D3-receptor (8) and could hinder the access of the antipsychotics to the D3-receptors in the islands of Calleja. Nemonapride, which is the only test compound with subnanomolar affinity in vitro for D3-receptors (slightly more potent than its D2 affinity), also showed a sixfold decrease in ratio of D2 vs D3 interaction potency as compared to its in vitro ratio. D1-receptor occupancy could be demonstrated for clozapine, with a two times lower potency than its D2-receptor occupancy.
The measurement of D4-receptor occupancy in the rat brain still awaits the validation of a reliable model for D4-receptor labelling, which has not been achieved to date despite numerous attempts. 
Predominance of interaction with S-HT2A-receptors vs D2-receptors
The predominance of 5-HT2A-vs D2-antagonism is believed to be an important factor for obtaining the therapeutic properties of "atypical neuroleptics"; tenfold higher affinity in vitro for 5-HT2A-receptors vs D2-receptors being the minimal requirement (21) . Among the compounds analyzed here, only risperidone, 9-OHrisperidone and clozapine fulfil this requirement. However, the present study goes a step further by also analyzing the ratios of the in vivo occupancy of receptors at 2 hr after s.c. administration.
Peak occupancy of receptors usually occurs within 1 hr after s.c. administration.
Risperidone, 9-OH-risperidone, SM-9018, clozapine and clocapramine showed higher affinity for 5-HT2A-than for D2-receptors in vitro. Mosapramine, haloperidol, bromperidol and nemonapride showed a slight to high predominance of D2-receptor compared to 5-HT2A-receptor affinity. In vivo data confirmed the in vitro observations (Tables 4 and 5 ). Both in vitro and in vivo, risperidone displayed the highest predominance for 5-HT2A-receptor vs D2-receptor interaction (17-and 19-fold, respectively). For 9-OH-risperidone predominance of 5-HT2A-receptor vs D2-receptor interaction was also obvious (16-and 11-fold, in vitro and in vivo, respectively). Only risperidone and 9-OH-risperidone showed a greater than tenfold higher potency for the in vivo occupancy of 5-HT2A-receptors vs D2-receptors. For risperidone, 9-OHrisperidone, SM-9018 and clocapramine, 5-HT2A-receptor occupancy was also the primary property in vivo. The ratios for 5-HT2A-receptor vs D2-receptor occupancy in vivo were in good agreement with the ratios of in vitro binding affinity for all compounds, except for clozapine that had a 46-fold higher affinity for 5-HT2A-receptors in vitro but only a fivefold preference in vivo.
Possible significance of predominant 5-HT2A-receptor antagonism vs D2-receptor antagonism A complex interaction between the serotonergic and dopaminergic systems seems to exist. It has been shown that the 5-HT2A antagonist ritanserin increased both burst firing and firing rate of midbrain dopaminergic neurons (18) , indicating that 5-HT exerts (probably indirectly) an inhibitory control of midbrain dopaminergic neurons. In an animal model of hypofrontality, a phenomenon that has been associated with negative symptoms of schizophrenia, the activity of midbrain dopaminergic neurons projecting to the frontal cortex is deadened to pacemaker activity by local cooling of the frontal cortex. 5-HT2A antagonists can restore the dopaminergic burst firing in these conditions (19) . Similarly, in animals treated with low doses of the dopamine antagonist raclopride, co-treatment with ritanserin could restore burst firing (=signal) and reduce tonic activity (=noise) of midbrain dopaminergic neurons. However, restoration of burst firing by the 5-HT2A antagonist could no longer be achieved when higher doses of raclopride were used (19) . This suggests the importance of the ratio between 5-HT2A-and D2-receptor occupancy for obtaining the optimal regulation of the dopaminergic neurotransmission by 5-HT2 antagonism. The restoration of regular burst firing of midbrain dopaminergic neurons is likely to play a role in the treatment of the negative symptoms of schizophrenia.
5-HT2A antagonism is also known to reduce the neuroleptic-induced side effects both in rats and patients (14) (15) (16) (17) . It was demonstrated in this respect that blockade of 5-HT2A-receptors attenuated the effects of D2 blockade on dopaminergic transmission in rat striatum but not on mesolimbic dopaminergic neurons (20) , supporting the idea that 5-HT2A antagonism has an important role in the reduction of EPS. However, to benefit from these regulating properties, an extensive blockade of 5-HT2A-receptors needs to be combined with a milder D2 antagonism, leaving enough D2-receptors unoccupied by the antipsychotic drug to receive the signal of the restored dopaminergic transmission. This condition can be achieved with risperidone better than with any of the other compounds analyzed in this study.
Interaction with various neurotransmitter receptors
Besides affinity for 5-HT2A-and D2-receptors, the compounds also showed moderate to high occupancy of a1-receptors, except for clocapramine and nemonapride. Yet, the significance of central adrenergic a1-receptor occupancy is not quite clear. Only risperidone and clozapine occupied adrenergic a2-receptors. Clozapine's primary affinity in vitro is for H1-receptors, which was 30 times higher than its D4 affinity and 70 times higher than its D2 affinity. The in vivo data confirmed both its predominant occupancy of H1-receptors (47 times more potent than D2-receptor occupancy) and potent occupancy of cholinergic-receptors (equivalent to D2-receptor occupancy). The occupancy of muscarinic receptors by clozapine may contribute to its particular clinical profile but may also be responsible for side effects like hypersalivation. The latter effect may in part be explained by clozapine's selective agonism for muscarinic M4-receptors (although being an antagonist at the other muscarinic subtypes) (71) . The extensive sedation caused by clozapine (72) is most likely due to the H1-receptor occupancy. Risperidone, and to a lesser extend 9-OH-risperidone, also showed an occupancy of H1-receptors in the guinea pig cerebellum. However, from in vitro binding experiments using cloned human H1-receptors, it appeared that risperidone shows a 6-times lower affinity for the human H1-receptor than for the guinea pig one, whereas clozapine shows the same affinity for both receptors (K. De Loore, manuscript in preparation). In vitro affinity for a1-receptors was reported for haloperidol, bromperidol, nemonapride and SM-9018, but since a participation of this receptor in the therapeutic properties of antipsychotic compounds seems unlikely, occupancy of the latter site was not investigated in vivo.
Course of interaction and regional interaction with dopamine D2-receptors For increasing dosages, risperidone displayed a more gradual D2-receptor occupancy than the other drugs. 9-OH-Risperidone showed similarly a tendency towards more gradual occupancy of D2-receptors in the striatum. The drugs classified as typical neuroleptics like haloperidol and bromperidol showed steeper curves for the occupancy of D2-receptors in the rat brain; the slopes of the curves were significantly different from that of risperidone (Table 6 ). The more gradual occupancy curve of risperidone is in line with previous behavioral observations which showed that a much wider dose-range was required between the inhibition of evoked dopaminergic responses (low D2-receptor blockade) and the occurrence of catalepsy in rats (high D2-receptor blockade) with risperidone than with haloperidol (22) . In other experiments it was demonstrated in rats that the disinhibition by risperidone of locomotor activity induced by a high dose of amphetamine was maintained over a wider dose range before reaching immobility (high D2-receptor blockade) (73) than with haloperidol. The slopes of the occupancy curves of adrenergic al-receptors were never significantly different from the slopes for D2-receptor occupancy curves in the caudate-putamen.
The slopes of the 5-HT2A-receptor occupancy curves were not different from those of D2-receptor occupancy in the caudate-putamen except for risperidone that showed a steeper 5-HT2A-receptor occupancy and clozapine that displayed a more gradual 5-HT2A-receptor occupancy than their respective D2-receptor occupancies. The reason for these two discrepancies is not understood. In both cases however, slopes of the 5-HT2A occupancy curves were not different from slopes for the al-receptor occupancy.
Further experiments are required to determine if risperidone exhibits a more gradual occupancy of D2-receptors also in humans. Such a property could effectively contribute to risperidone's ability to avoid extrapyramidal side effects at therapeutic dosages. Indeed, a compound with a more shallow curve for D2-receptor occupancy could benefit from this property by better avoiding the extensive occupancy of striatal D2-receptors, which is believed to cause extrapyramidal side effects.
An advantage of ex vivo autoradiography is certainly its high anatomical resolution allowing regional measurement of receptor occupancy in vivo, which is of particular interest for the dopaminergic pathways. It is accepted that occupancy of D2-receptors located in the mesolimbic system plays an important role in the therapeutic properties of antipsychotic drugs, while an extensive occupancy of striatal D2-receptors is believed to produce the neurological side-effects. One can therefore suppose that a preferential D2-receptor occupancy in the mesolimbic system may be propitious. However, none of the compounds investigated in this study showed any regional preference for D2-receptor occupancy in mesolimbic vs nigrostriatal areas. Each of them showed ED50 doses with overlapping 95% confidence limits among the four dopaminergic areas analyzed.
Conclusions
In view of the above results, it can be concluded that risperidone is different from the other compounds in this study. The predominance of 5-HT2A-receptor vs D2-receptor occupancy and the more gradual occupancy of D2-receptors differentiate risperidone from the other antipsychotic compounds. These properties probably underlie the excellent clinical results obtained with risperidone in schizophrenic patients.
